Search
Search Results
##search.searchResults.foundPlural##
-
Pathogen distribution, antimicrobial resistance, and mortality in febrile neutropenia among adults with hematological malignancies: a single-center cohort study
103PDF: 40Suppl. Files: 13Html: 27Html Suppl. Files: 7 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2878PDF: 1024HTML: 610 -
Brief tale of a bacteraemia by Rhodococcus equi with concomitant lung mass: what came first, the chicken or the egg?
1536PDF: 895HTML: 8690Fig 3 Savini: 244Fig 2 Savini: 240Fig 1 Savini Chest TC: 235Author letter to referees: 239 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1948PDF: 663HTML: 378 -
COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN INDIA
2934PDF: 1049HTML: 4754 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
2155PDF: 856HTML: 737Table1: patient's characteristics: 255Table 2: profile of each patient: 236 -
Osteolytic bone lesions – A rare presentation of AML M6.
2131PDF: 1224HTML: 8021Untitled: 254 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1755PDF: 1206HTML: 278 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
3304PDF: 974HTML: 6632Untitled: 292Untitled: 247Untitled: 271Untitled: 275 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1597PDF: 1430HTML: 125 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3374PDF: 1443HTML: 4169 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2417PDF: 960HTML: 2032Fig 1 Rossi: 250 -
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
4508PDF: 1475HTML: 2213 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1644PDF: 1353HTML: 545 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
3113PDF: 1106HTML: 5675 -
Severe eosinophilia in a case of giardiasis
1188PDF: 1657HTML: 471 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
5215PDF: 3023HTML: 2383 -
ANORECTAL PATHOLOGIES IN THE COURSE OF ACUTE LEUKAEMIAS: PREDICTIVE PARAMETERS Anorectal pathologies in leukemias
1335PDF: 826Html: 131 -
-
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1937PDF: 1275HTML: 367 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
2513PDF: 668HTML: 390







